2OT5

Crystal structure of the HIV gp41 core with the enfuvirtide resistance mutation N43D


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free: 0.258 
  • R-Value Work: 0.234 
  • R-Value Observed: 0.234 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.

Bai, X.Wilson, K.L.Seedorff, J.E.Ahrens, D.Green, J.Davison, D.K.Jin, L.Stanfield-Oakley, S.A.Mosier, S.M.Melby, T.E.Cammack, N.Wang, Z.Greenberg, M.L.Dwyer, J.J.

(2008) Biochemistry 47: 6662-6670

  • DOI: https://doi.org/10.1021/bi702509d
  • Primary Citation of Related Structures:  
    2OT5, 3CP1, 3CYO

  • PubMed Abstract: 

    Enfuvirtide (ENF), the first human immunodeficiency virus type 1 (HIV-1) fusion inhibitor approved for clinical use, acts by binding to gp41 heptad repeat 1 (HR1) and preventing its interaction with the viral HR2 region. Treatment-emergent resistance to ENF has been mapped to residues within HR1, and these mutations decrease its susceptibility to ENF and may reduce viral fitness and pathogenesis, although the mechanism for these effects is not clear. N43D, a common ENF resistance mutation, was found in in vitro assays to cause a 5-50-fold in antiviral activity. We introduced this mutation into peptide models and determined the impact of this mutation by circular dichroism and X-ray crystallography. We find that the mutation results in a decrease in the thermal stability of the six-helix bundle and causes a significant change in the HR1-HR2 interface, including a loss of HR2 helicity. These data form a mechanistic basis for the decrease in ENF sensitivity and six-helix bundle stability. The E137K polymorphism, generally present at baseline in patients who develop N43D, partially compensates for the loss of stability, and we show that these residues likely form an ion pair. These data form a framework for understanding the impact of resistance mutations on viral fitness and pathogenesis and provide a pathway for the development of novel fusion inhibitor peptides.


  • Organizational Affiliation

    Protein Engineering Group and Virology Group, Trimeris, Inc., 3500 Paramount Parkway, Morrisville, North Carolina 27560, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
HIV-1 gp41 glycoprotein68N/AMutation(s): 0 
UniProt
Find proteins for Q53I19 (Human immunodeficiency virus 1)
Explore Q53I19 
Go to UniProtKB:  Q53I19
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ53I19
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free: 0.258 
  • R-Value Work: 0.234 
  • R-Value Observed: 0.234 
  • Space Group: H 3
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 51.025α = 90
b = 51.025β = 90
c = 59.668γ = 120
Software Package:
Software NamePurpose
d*TREKdata scaling
CNSrefinement
PDB_EXTRACTdata extraction
CrystalCleardata collection
d*TREKdata reduction
CNSphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2008-06-17
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Derived calculations, Version format compliance
  • Version 1.2: 2023-08-30
    Changes: Data collection, Database references, Refinement description